<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230130057274N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-31</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of stress inoculation training approach on premenstrual syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of stress inoculation training (SIT) counseling approach on anxiety, and depression of students with premenstrual syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74663</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Subjects are randomly divided into two groups after applying the inclusion and exclusion criteria in the form of random allocation using the alternative block method. The size of the blocks is 4 and using the statistical software, 4 blocks will be produced 25 times. Considering that the sampling is done in one center, a sample list of 100 items will be produced. Using this randomly generated list, the participants are assigned to two groups of 50 people. The random sequence of people in the intervention or control groups is done through block building with a ratio of 1:1, and the researcher cannot predict the placement of the next person in any of the two groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety and depression.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, SIT therapy method is performed individually, which includes 6 consecutive sessions (one session per week) and the duration of each session is 30-45 minutes. The content of the meetings includes:The first session: Conceptualization of the therapeutic model, gaining awareness about the relationship between premenstrual syndrome and negative emotions, acquiring the skills to identify and evaluate thoughts and feelings, relaxation techniquesThe second session: acquiring the ability to identify negative automatic thoughts and begin to change them, relaxation techniquesThe third session: acquiring the ability to recognize cognitive errors, relaxation techniquesThe fourth session: acquiring the skill of correcting auto-negative thoughts, calming techniques  The fifth session: acquiring the ability to evaluate daily activities, stress coping techniques, relaxation techniquesThe sixth session: developing effective coping plans for stress, challenges of ending treatment, complete relaxation techniques. Intervention 2: Control group: This group of students does not receive SIT treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Confidentiality</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hajar Adib-Rad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Midwifery, School of Medicine, Babol University of Medical Sciences, Ganj Afrooz St., Babol, Iran</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 3219 0597</telephone>
        <email>Adibrad2015@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hajar Adib-Rad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Midwifery, School of Medicine, Babol University of Medical Sciences, Ganj Afrooz St., Babol, Iran</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 3219 0597</telephone>
        <email>Adibrad2015@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being Iranian
Students living in the student dormitory of Babol University of Medical Sciences
Declaration of consent to participate in the study
Having premenstrual syndrome
Having regular menstrual cycles with intervals of 21 to 35 days and a duration of 3 to 7 days at least during the last six months
Having 5 symptoms of premenstrual syndrome for two consecutive months
Having symptoms of depression or anxiety with a score of 8 or higher
Access to the smartphone
Age range from 18 to 38 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>38 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Use of antidepressants and anxiety medications during the study
Participation in other psychological interventions such as psychotherapy, meditation, yoga
Occurrence of stressful events at least six months before the start of the study
Suffering from genital diseases and known and chronic underlying diseases
Taking birth control pills
Hormonal disorders and irregular menstruation
Current or history of severe mental illness such as severe depression, bipolar disorder, and suicidal thoughts
Drug addiction and consumption of psychoactive substances or alcohol</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F41.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mixed anxiety and depressive disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, SIT therapy method is performed individually, which includes 6 consecutive sessions (one session per week) and the duration of each session is 30-45 minutes. The content of the meetings includes:The first session: Conceptualization of the therapeutic model, gaining awareness about the relationship between premenstrual syndrome and negative emotions, acquiring the skills to identify and evaluate thoughts and feelings, relaxation techniquesThe second session: acquiring the ability to identify negative automatic thoughts and begin to change them, relaxation techniquesThe third session: acquiring the ability to recognize cognitive errors, relaxation techniquesThe fourth session: acquiring the skill of correcting auto-negative thoughts, calming techniques  The fifth session: acquiring the ability to evaluate daily activities, stress coping techniques, relaxation techniquesThe sixth session: developing effective coping plans for stress, challenges of ending treatment, complete relaxation techniques</i_keyword>
      <i_keyword>Control group: This group of students does not receive SIT treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Hospital anxiety and depression questionnaire.</prim_outcome>
      <prim_outcome>Depression. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Hospital anxiety and depression questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Stress. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Perceived Stress Questionnaire 14.</sec_outcome>
      <sec_outcome>Performance. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Sheehan's Disability Questionnaire.</sec_outcome>
      <sec_outcome>Psychological well-being. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Riff's Psychological Well-Being Questionnaire.</sec_outcome>
      <sec_outcome>Symptoms of premenstrual syndrome. Timepoint: Before the intervention, immediately after the end of the intervention in the luteal phase, the first and second menstrual cycle after the intervention. Method of measurement: Premenstrual Symptoms Screening Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-30</approval_date>
        <contact_name>Health Research Institute - Babol University of Medical Sciences (Research Ethics Committee)</contact_name>
        <contact_address>Ganj Afrooz St., Babol University of Medical Sciences Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
